In brief: Acrux, Meditech, Psivida
Tuesday, 03 May, 2005
Melbourne's Acrux (ASX: ACR) has Adam Watkinson as its chief scientific officer. Watkinson is currently manager of drug delivery research and project manager at UK pharmaceutical company ProStrakan .
Meditech Research's (ASX: MTR) Ian Nisbet is to present the company's business plans and product data at the Rodman & Renshaw Global Healthcare Conference in Paris on May 5.
pSivida Limited (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) is to present the interim data from its Phase IIa BrachySil trial in patients with primary liver cancer to the European Society for Therapeutic and Radiation Oncology Conference in Budapest on May 5.
Psivida has reported that both patient cohorts from the Phase IIa trial show the product is safe and effective in prompting tumour regression.The final data is expected to be released in June.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
